AbbVie

News

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has hit a snag.

Views & Analysis

R&D roundup – Sage impresses at JP Morgan

One of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling promising data from an up-rated phase III trial of its postpartum

News

AbbVie suffers fresh setback with lung cancer drug Rova-T

AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.

News

AbbVie, Pfizer reach licencing agreement for biosimilar Humi...

AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting Pfizer’s patent dispute and allowing AbbVie

News

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

BMS, AbbVie get FDA OK for new myeloma regimen

Bristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they hope will help drive uptake of the drug.

AbbVie and J&J’s Imbruvica fails pancreatic cancer test

R&D roundup – Sage impresses at JP Morgan

AbbVie suffers fresh setback with lung cancer drug Rova-T

AbbVie, Pfizer reach licencing agreement for biosimilar Humi...

NHS saving £300m with Humira biosimilar deal

BMS, AbbVie get FDA OK for new myeloma regimen

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AbbVie

Editor's Picks